Internal Medicine, Nephrology · Wayne, NJ
NPI
1598762148
Since 2005
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
342 Hamburg Tpke, Ste 201
Wayne, NJ, 07470
Phone (973) 389-1119
Groups this clinician bills Medicare through
Medicare paid, 2024
$138K
2,468 services
Medicare patients, 2024
478
Average age 78
Drug cost, 2024
$483K
2,680 prescriptions
Company payments, 2025
$365
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kevin E Vitting was code 99232 (hospital e&m - subsequent), 917 times for 167 patients. In total Kevin E Vitting billed 2,468 services in 20 codes, and Medicare paid $138K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-03-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 917 | 167 | $66.48 | $61K |
| 99213 Office E&M - Established | Office | 390 | 218 | $54.55 | $21K |
| 99214 Office E&M - Established | Office | 198 | 118 | $59.63 | $12K |
| 99222 Hospital E&M - Initial | Facility | 173 | 130 | $110.14 | $19K |
| 99221 Hospital E&M - Initial | Facility | 105 | 97 | $69.86 | $7,335 |
| 99306 SNF E&M | Office | 55 | 55 | $144.10 | $7,925 |
| 81000 Clinical Chemistry | Office | 31 | 31 | $3.94 | $122 |
| 99203 Office E&M - New | Office | 26 | 26 | $91.56 | $2,381 |
| 99233 Hospital E&M - Subsequent | Facility | 20 | 18 | $99.51 | $1,990 |
| 99204 Office E&M - New | Office | 17 | 17 | $130.89 | $2,225 |
By year: 2022 $183K for 2,224 services; 2023 $129K for 1,900 services; 2024 $138K for 2,468 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81000 Clinical Chemistry | 31 | 31 | $3.94 | $122 |
Medicare prescription drug claims, 2024
In 2024, the drug Kevin E Vitting prescribed most often to Medicare patients was Furosemide, with 188 prescriptions and refills. In total Kevin E Vitting wrote 2,680 Medicare prescriptions that cost $483K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Furosemide Generic | 188 | 500 | 63 | $1,425 |
| Amlodipine Besylate Generic | 170 | 440 | 57 | $1,068 |
| Atorvastatin Calcium Generic | 122 | 355 | 41 | $1,236 |
| Jardiance Empagliflozin | 105 | 157 | 22 | $92K |
| Valsartan Generic | 99 | 291 | 31 | $3,487 |
| Metoprolol Succinate Generic | 95 | 270 | 33 | $1,348 |
| Sodium Polystyrene Sulfonate Generic | 94 | 177 | 44 | $7,773 |
| Farxiga Dapagliflozin Propanediol | 78 | 120 | 15 | $63K |
| Gabapentin Generic | 69 | 135 | 21 | $1,019 |
| Allopurinol Generic | 67 | 193 | 21 | $470 |
| Sevelamer Carbonate Generic | 66 | 148 | 23 | $15K |
| Cinacalcet Hcl Generic | 64 | 148 | 20 | $23K |
| Losartan Potassium Generic | 54 | 158 | 20 | $515 |
| Lisinopril Generic | 49 | 145 | 21 | $296 |
| Levothyroxine Sodium Generic | 42 | 125 | 13 | $564 |
Brand drugs: - claims; generic drugs: 2,269 claims; opioid claims: 20.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kevin E Vitting $365 ($365 in general payments such as food, travel and fees) from 10 companies. The largest payer was Travere Therapeutics, Inc. with $71.88.
| Company | Payments | Amount |
|---|---|---|
| Travere Therapeutics, Inc. TVTX | 4 | $71.88 |
| Akebia Therapeutics Inc AKBA | 3 | $58.54 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 2 | $37.15 |
| Mallinckrodt Hospital Products Inc. | 2 | $36.11 |
| Novartis Pharmaceuticals Corporation NVS | 2 | $35.16 |
| Lilly USA, LLC LLY | 2 | $32.58 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 2 | $28.32 |
| Scpharmaceuticals Inc. SCPH | 1 | $23.06 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. 4578.T | 1 | $21.44 |
| ANI Pharmaceuticals, Inc. ANIP | 1 | $21.17 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.